{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:27:59Z","timestamp":1771230479171,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00277-020-04171-7","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T08:42:27Z","timestamp":1596098547000},"page":"2821-2829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A\u2014results of a retrospective analysis"],"prefix":"10.1007","volume":"99","author":[{"given":"M.","family":"Pouyiourou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"K\u00e4mpfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Monecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schmalenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Prange-Krex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-4086","authenticated-orcid":false,"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the East German Study Group for Hematology and Oncology (OSHO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"4171_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. In: WHO classification of tumours, Lyon. WHO reference number: 17024002. 266\u2013279"},{"issue":"10","key":"4171_CR2","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","volume":"99","author":"G Ott","year":"2002","unstructured":"Ott G, Katzenberger T, Lohr A, Kindelberger S, R\u00fcdiger T, Wilhelm M, Kalla J, Rosenwald A, M\u00fcller JG, Michaela Ott M, M\u00fcller-Hermelink HK (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 99(10):3806\u20133812","journal-title":"Blood."},{"key":"4171_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","volume":"96","author":"H Horn","year":"2011","unstructured":"Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, Kalla J, Romero M, Siebert R, Rosenwald A, Ott G (2011) Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 96:1327\u20131334","journal-title":"Haematologica."},{"issue":"7","key":"4171_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","volume":"103","author":"H Horn","year":"2018","unstructured":"Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Tr\u00fcmper L, Spang R, Rosenwald A, Ott G (2018) Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica. 103(7):1182\u20131190","journal-title":"Haematologica."},{"issue":"7","key":"4171_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","volume":"27","author":"K Koch","year":"2016","unstructured":"Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann ML, Bernd W, Stein H, P\u00f6schel V, Dreyling M, Tr\u00fcmper L, L\u00f6ffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W (2016) Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 27(7):1323\u20131329","journal-title":"Ann Oncol"},{"issue":"9","key":"4171_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, M\u00f6ller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111\u20131122","journal-title":"Lancet Oncol"},{"key":"4171_CR7","doi-asserted-by":"crossref","unstructured":"Casulo C (2018) Risk stratification in follicular lymphoma. Best Pract Res Clin Haematol 31(1):15\u201322","DOI":"10.1016\/j.beha.2017.11.002"},{"issue":"14","key":"4171_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trn\u011bn\u00fd M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344","journal-title":"N Engl J Med"},{"key":"4171_CR9","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, De Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mah\u00e9 B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 112:4824\u20134831","journal-title":"Blood."},{"issue":"23","key":"4171_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, D\u00fcrig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395\u20132404","journal-title":"J Clin Oncol"},{"issue":"19","key":"4171_CR11","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Van Der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19):2944\u20132952","journal-title":"Blood."},{"issue":"9873","key":"4171_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, Von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2 [Internet]","journal-title":"Lancet"},{"issue":"3","key":"4171_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjh.15656","volume":"184","author":"A Roisman","year":"2019","unstructured":"Roisman A, Castellano G, Navarro A, Gonzalez-Farre B, P\u00e9rez-Galan P, Esteve-Codina A, Dabad M, Heath S, Gut M, Bosio M, Bellot P, Salembier P, Oliveras A, Slavutsky I, Magnano L, Horn H, Rosenwald A, Ott G, Aymerich M, L\u00f3pez-Guillermo A, Jares P, Mart\u00edn-Subero JI, Campo E, Hern\u00e1ndez L (2019) Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas. Br J Haematol 184(3):373\u2013383","journal-title":"Br J Haematol"},{"key":"4171_CR14","doi-asserted-by":"crossref","unstructured":"Fisher RL, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23(33):8447\u201352","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"4171_CR15","doi-asserted-by":"crossref","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Parti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111(8):4004\u201313","DOI":"10.1182\/blood-2007-10-116749"},{"issue":"4","key":"4171_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","volume":"23","author":"P Mondello","year":"2018","unstructured":"Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist 23(4):454\u2013460","journal-title":"Oncologist"},{"key":"4171_CR17","doi-asserted-by":"crossref","unstructured":"Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N (2019) Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen. Clin Lymphoma Myeloma Leuk 19(2):95\u2013102","DOI":"10.1016\/j.clml.2018.11.010"},{"issue":"10","key":"4171_CR18","doi-asserted-by":"publisher","first-page":"E460","DOI":"10.3324\/haematol.2018.209080","volume":"104","author":"CB Steen","year":"2019","unstructured":"Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, \u00d8stenstad B, Liest\u00f8l K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingj\u00e6rde OC, Brodtkorb M (2019) A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. Haematologica. 104(10):E460\u2013E464","journal-title":"Haematologica."},{"issue":"17","key":"4171_CR19","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZS, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25(17):2426\u20132433","journal-title":"J Clin Oncol"},{"key":"4171_CR20","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Da Silva MG, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34(22):2575\u201382","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"4171_CR21","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","volume":"35","author":"MJ Rummel","year":"2017","unstructured":"Rummel MJ, Maschmeyer G, Ganser A, Heider A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk HA, Ballo H, Stauch M, Blau W, Burchardt A, Barth J, Kauff F, Brugger W (2017) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol 35:7501","journal-title":"J Clin Oncol"},{"issue":"12","key":"4171_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Van Der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984\u2013991. https:\/\/doi.org\/10.1200\/JCO.18.00605 [internet]","journal-title":"J Clin Oncol"},{"key":"4171_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood-2019-130208","volume":"134","author":"V Jurinovic","year":"2019","unstructured":"Jurinovic V, Passerini V, Oestergaard MZ, Knapp A, Mundt K, Araf S, Richter J, Fitzgibbon J, Klapper W, Marcus RE, Davies A, Herold M, Hiddemann W, Unterhalt M, Hoster E, Weigert O (2019) Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 134:122","journal-title":"Blood."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04171-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T23:20:26Z","timestamp":1627600826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04171-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04171-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AV has been on Advisory Boards for Amgen, Roche, Kite\/Gilead, and Novartis and received travel support and speaker honoraria from Amgen, Roche, Kite\/Gilead, and Janssen. PLR has been on the Advisory Board for Roche. GM has received honoraria for lectures from Gilead, Janssen Cilag, AMGEN, Merck-Serono, Bristol-Myers Squibb, and AstraZeneca and travel grants from Janssen Cilag. TW has received travel grants and has been on the Advisory Board for Roche. SB reports consulting fees from Roche and AbbVie, research funding from Roche, Janssen, AbbVie, and Celgene, and honoraria from Roche, AbbVie, Janssen, Novartis, and Becton Dickinson. HS has received speaker honoraria and has been on the Advisory Boards for Lilly, MSD, Roche, Novartis, BMS, Basilea, Merck Serono, and Servier and has received research support from Sanofi. RM has received speaker honoraria and has been on the Advisory Boards for Janssen, Merck, Eusa, Novartis, and Kite\/Gilead and has received travel grants from Kite\/Gilead. UK has received travel support, speaker support and speaker honoraria from Roche and travel support and speaker honoraria from Mundipharma. WK has received research grants from Roche, Takeda, Amgen and Regeneron. SWS has received speaker honoraria from Gilead, Janssen and Pfizer and has been on the Advisory Boards for Roche, Novartis, Janssen, Hexal, Gilead, Takeda, Daiichi Sankyo, Celgene, Bristol-Myers Squibb, and Merck Serono. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective analysis was approved by the ethics committee of the Berlin Chamber of Physicians. The study was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this is a retrospective analysis of patient data, no additional informed consent was required. Patient data was collected and analyzed in anonymized form. Dates of birth were provided as five-year intervals in order to avoid patient identification (i.e., 1950\u20131954 for a patient born in 1952).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}